-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, it has been reported that within 4 to 28 days after vaccination with the new coronary pneumonia vaccine ChAdOx1 nCov-19 (AstraZeneca/Oxford) and AD26.
Recently, it has been reported that within 4 to 28 days after vaccination with the new coronary pneumonia vaccine ChAdOx1 nCov-19 (AstraZeneca/Oxford) and AD26.
Mayte Sánchez van Kammen and others discussed the incidence of thrombocytopenia, heparin-induced thrombocytopenia and platelet factor 4/heparin antibodies in patients with cerebral venous sinus thrombosis before the new coronary pneumonia epidemic
Of the 952 patients, 865 had a baseline platelet count available
Of the 952 patients, 865 had a baseline platelet count available
The main outcome measures were admission thrombocytopenia (platelet count <150×10 3 /μL), heparin-induced thrombocytopenia ( diagnosed by the treating doctor ) and platelet factor 4/heparin IgG antibody (optical density> 0.
The platelet count of 56 patients with cerebral venous sinus thrombosis and thrombocytopenia on admission and discharge
The platelet count of 56 patients with cerebral venous sinus thrombosis and thrombocytopenia on admission and dischargeAmong 865 patients (median age 40 years old [interquartile range 29 to 53 years old], 70% women), 73 cases of thrombocytopenia (8.
Among 865 patients (median age 40 years old [interquartile range 29 to 53 years old], 70% women), 73 cases of thrombocytopenia (8.
In this study, thrombocytopenia was not common in 865 patients with CVST before the COVID-19 pandemic
In patients with cerebral venous sinus thrombosis before the new coronary pneumonia epidemic, baseline thrombocytopenia is uncommon, and heparin-induced thrombocytopenia and platelet factor 4/heparin antibody are rare.
Original source
Sánchez van Kammen M, Heldner MR, Brodard J, et al.
Sánchez van Kammen M, Heldner MR, Brodard J, et al.
Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic.
JAMA.
2021;326(4):332– 338.
doi:10.
1001/jama.
2021.
9889 Sánchez van Kammen M, Heldner MR, Brodard J, et al.
Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic.
JAMA.
Leave a message here